"We see ValidCare as a critical platform in enabling a quantifiable, deep understanding of the impact of CBD products,” says Matty Mangone-Miranda, CEO of GenCanna. “This partnership is essential in paving the path forward to providing CBD to the millions of people who need it."
CENTENNIAL, Colo. (PRWEB) September 27, 2018
GenCanna Global, Inc. has entered into a multi-year, strategic advisement and membership agreement with ValidCare, LLC, to measure the benefits of hemp-derived CBD for global consumers. GenCanna is a Kentucky-based agriculture-technology company specializing in the production of CBD-rich hemp. The company’s founders and executive team have been at the forefront of innovation in the hemp CBD and cannabis industries for over twenty years.
ValidCare brings together businesses, research organizations, clinicians and others in the CBD-product community to improve consumer experiences resulting from cannabis-based products. ValidCare provides Insights-as-a-Service via technology that includes a trusted, secure private network, advanced machine learning, and a proprietary user interface to build shared knowledge and power product development.
The unique ValidCare community model gives companies like GenCanna the ability to derive real-time insights from patients and product consumers, enabling a better understanding of the benefits of CBD products. “Communication between patients, health consumers, clinicians and suppliers is critical to further the understanding of the possible benefits of CBD products. Our partnership with ValidCare will be integral to this effort, and collectively we believe we will drive the industry forward in a more substantive manner than we have seen in the past,” said Chris Stubbs, Chief Science Officer, GenCanna Global.
Supplier members of ValidCare can communicate directly with patients and health consumers in new ways, delivering product information, education and compassionate use programs, and through user-specific research studies. Resulting consumer insights can then be used to advance scientific and commercial efforts, from seed to outcomes.
In addition to joining the ValidCare community, GenCanna will sit on ValidCare’s Product Council and have an expanded advisory role that the companies are finalizing. “We see ValidCare as a critical platform in enabling a quantifiable, deep understanding of the impact of CBD products,” says Matty Mangone-Miranda, CEO of GenCanna. “This partnership is essential in paving the path forward to providing CBD to the millions of people who need it. At GenCanna, we are committed to further understanding and expanding cannabinoid use. Unfortunately, today there is still a limited understanding within the cannabis industry about the full capabilities of the plant. We believe this partnership will be critical in expanding that understanding while driving the market toward proper usage.”
“We are excited to welcome GenCanna Global to the ValidCare community. GenCanna is a proven industry leader, from genetics through finished product, and will play an instrumental role on our advisory boards,” said Patrick McCarthy, CEO of ValidCare. “They support our mission to connect, collect and inform. With our growing global community, we can build and share insights that help industry leaders like GenCanna create the most effective products, and consumers to participate fully in the management of their health. We want to help people live healthier lives.”
# # #
About ValidCare, LLC
ValidCare, LLC is the cannabinoid (CBD) industry’s Insights-as-a-Service company, connecting the global CBD community, collecting experiential data to drive product development and informing the community on CBD’s impact on health. The ValidCare platform offers a trusted and secure private network where product suppliers and developers, researchers, clinicians, and product users and their families come together to study, educate, measure and document the consumer experience with CBD treatments. ValidCare’s CBD+Me proprietary app supports ongoing two-way communication, combining consumer-reported data with advanced machine learning to deliver insights that help accelerate validated treatment options. For more information, visit http://www.validcare.com or call 844-825-4322.